In contrast, NTRK2 expression in neuroblastoma has been reported to be associated with MYCN amplification, enhanced migratory properties leading to early metastases and a resistance to first-line chemotherapeutics, all of which contribute to poor patient survival (20, 22–24). The gene discussed is NTRK2; the disease is neuroblastoma.